Drug, bio-affecting and body treating compositions inventions 12/06

20060293216 - Pharmaceutical compositions comprising an active agent and chitosan for sustained drug release or mucoadhesion: The invention provides a pharmaceutical composition comprising a physiologically active agent and a release sustaining or mucoadhesive agent, characterized in that said release sustaining or mucoadhesive agent comprises a chitosan having a FA of from 0.25 to 0.80.... Agent: Sughrue Mion, PLLC

20060293217 - Pharmaceutical formulations for sustained release: Sustained delivery pharmaceutical compositions comprising a solid ionic complex of a pharmaceutically active compound and an ionic macromolecule are provided by the present invention. The pharmaceutical compositions of the invention allow for loading of high concentrations of pharmaceutically active compounds and for delivery of a pharmaceutically active compound for prolonged... Agent: Lahive & Cockfield, LLP

20060293218 - Salicylate therapeutic compound and process for controlled delivery thereof: A therapeutic composition includes a salicylate administering concert with at least one salicylate excretion compound of a glycine salicylate conjugate and a gluconoride salicylate conjugate. A therapeutic composition is provided that has an extended excretion half-life for a salicylate that includes the administration of the salicylate in concert with an... Agent: Gifford, Krass, Groh, Sprinkle & Citkowski, P.c

20060293219 - Methods of treating diabetes mellitus: Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may “activate” the liver, potentially restoring normal glucose homeostasis to... Agent: Moore & Van Allen PLLC

20060293220 - Calcium phosphate nanoclusters and their applications: Artificial particles known as calcium phosphate nanoclusters are disclosed. The particles contain high concentrations of calcium, particularly for use in nutritional products, neutraceuticals, and pharmacological preparations.... Agent: Fleshner & Kim, LLP

20060293222 - Methods of inducing ovulation: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's... Agent: Howrey LLP

20060293221 - Mucosal repair by tff2 peptides: The present invention relates to the use of trefoil factor 2 (TFF2) peptides and a pharmaceutical composition comprising TFF2 peptides for increasing the viscosity of mucin in mucus layers and the repair of damaged mucus layers in the gastrointestinal tract (mouth, oesophagus, stomach, small and large intestine, colon) the respiratory... Agent: Novo Nordisk, Inc. Patent Department

20060293224 - Conformationally stabilized cell adhesion peptides: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide... Agent: Mcdermott, Will & Emery

20060293223 - Uses of melanocortin-3 receptor (mc3r) agonist peptides: The present invention provides methods of treating metabolic disorders, including, for example, obesity, diabetes mellitus, cachexia, sarcopenia, and cardiovascular disorders, methods of inducing weight loss and increasing muscle mass in a patient, by administration of MC3R agonist peptides. Furthermore, the present invention provides the use of an MC3R agonist peptide... Agent: Eli Lilly & Company

20060293233 - Compositions and methods for modulating body weight and treating obesity-related disorders: The present invention relates to compositions and methods for regulating body weight, and for treating conditions associated with obesity, particularly, obesity-related diabetes. The present invention is premised on the discovery that body weight can be effectively regulated by modulating the levels and/or activities of two gut hormones, PYY and ghrelin.... Agent: Scully Scott Murphy & Presser, PC

20060293227 - Cosmetic compositions and methods using transforming growth factor-beta mimics: The invention provides methods, compositions, and kits for a variety of cosmetic uses, where the methods, compositions and kits utilize substances that display one or more activities of transforming growth factor-β (TGF-β mimics). Compositions, methods, and kits contain TGF-β mimics.... Agent: Wilson Sonsini Goodrich & Rosati

20060293230 - Expression and secretion of icil-1 receptor antagonist type ii: Novel glycosylated intracellular IL-1 receptor antagonist type II (icIL-1ra-II) is expressed and secreted in mammalian cells transformed with an expression vector where icIL-1ra-II is secreted by expressing icIL-1ra-II fused to the human growth hormone signal peptide. Also disclosed are a pharmaceutical composition containing glycosylated icIL-1ra-Il as an active ingredient and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20060293225 - Gmg-2 polynucleotides and polypeptides and uses thereof: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of GMG-2 polypeptide fragment comprising globular domain and all or part of GMG-2 collagen-like region, has been identified that has utility for reducing body mass, for... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20060293235 - Hgf beta chain variants: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.... Agent: Genentech, Inc.

20060293240 - Human sef isoforms and methods of using same for cancer diagnosis and gene therapy: A method and pharmaceutical compositions useful for inhibiting the growth of solid tumors are provided. Specifically, the method is effected by administering to a subject in need thereof an agent capable of upregulating the expression level and/or activity of at least a functional portion of Sef, wherein the functional portion... Agent: Martin D. Moynihan Prtsi, Inc.

20060293232 - Hybrid polypeptides with selectable properties: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are... Agent: Arnold & Porter LLP (18528)

20060293238 - Inactivation resistant factor viii: The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences of the present invention also encode amino acid... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20060293236 - Injectable osteogenic formula and method of using same: Formulations and methods for growing bone in a site specific location using an osteogenic molecule such as a prostaglandin, and a delivery vehicle which is preferably a polymer matrix.... Agent: Mirick, O'connell, Demallie & Lougee

20060293226 - Medicament and use thereof for tumor therapy: The invention relates to a medicament for tumor therapy, containing a first and a second molecule in an effective concentration, the first molecule representing a1) Annexin V or a molecule that is largely similar thereto, or a2) an effective fragment of Annexin V or the molecule that is largely similar... Agent: Fish & Richardson P.C.

20060293231 - Method for enhancing bone formation: This invention provides a method for facilitating bone formation in a subject comprising delivering to a bone formation-requiring site a composition of matter comprising platelet-rich plasma, calcium, a PAR-activating agent and a bone forming material. This invention further provides a method for facilitating bone formation in a subject comprising (a)... Agent: Cooper & Dunham, LLP

20060293241 - Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocaproic acid: The present invention relates to compositions or kits comprising factor VII or a factor VII-related polypeptide and epsilon-aminocaproic acid, and the use thereof for the treatment of bleeding episodes or enhancement of hemostasis.... Agent: Novo Nordisk, Inc. Patent Department

20060293237 - Psiepsilonrack peptide composition and method for protection against tissue damage due to ischemia: A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event.... Agent: Perkins Coie LLP

20060293229 - Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor: Site-specific isotopically-labeled valine, leucine, and isoleucine and biosynthetic precursors for these amino acids are provided. The amino acids are labeled with 13C or 14C at the methyl group carbon atom(s) most remote from the carboxyl group. Also disclosed are the biochemical precursors of these labeled amino acids, 2-keto-4-(nC) butyric acid... Agent: Wood, Phillips, Katz, Clark & Mortimer

20060293228 - Therapeutic compositions and methods using transforming growth factor-beta mimics: The invention provides methods, compositions, and kits for treating a variety of conditions using substances that display one or more activities of transforming growth factor-β (TGF-β mimics). Conditions include skin conditions, wounds, and the need for soft tissue augmentation. Compositions that may be used to treat such conditions contain a... Agent: Wilson Sonsini Goodrich & Rosati

20060293234 - Therapeutic peptides for the treatment of metastatic cancer: Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.... Agent: Banner & Witcoff

20060293239 - Treatment and diagnosis of insulin-resistant states: Dickkopf-5 (Dkk-5) protein is administered in effective amounts to treat disorders involving insulin resistance, such as non-insulin-dependent diabetes mellitus (NIDDM) or obesity. Also provided is a method of diagnosing insulin resistance and related disorders using Dkk-5 as a measure, and kits for diagnosis and treatment, as well as hybridomas producing... Agent: Merchant & Gould PC

20060293242 - Transporting of taxoid derivatives through the blood brain barrier: Taxoid derivatives are used in the treatment of cancers, particular cancers of the central nervous system, such as brain cancers. Taxoid derivatives are transported across the blood/brain barrier (BBB). A compound is provided which consists of at least one taxoid derivative bound to at least one vector peptide capable of... Agent: Bachman & Lapointe, P.C.

20060293244 - Anti-inflammatory compounds and uses thereof: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell.... Agent: Lahive & Cockfield, LLP

20060293243 - Stable, buffered, pharmaceutical compositions including motilin-like peptides: Stable, pharmaceutical compositions including a synthetic motilin-like peptide in a buffered solution are disclosed. The composition provides for a peptide that remains stable and substantially retains its initial potency during extended storage and after steam sterilization.... Agent: Baxter Healthcare Corporation

20060293246 - Methods of modulating beta cell function: Methods of modulating pancreatic function by modulating MCH signaling in a β cell.... Agent: Fish & Richardson PC

20060293245 - P21 derived peptides and uses thereof: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving... Agent: Lahive & Cockfield, LLP

20060293247 - Trh-like peptide derivatives as inhibitors of the trh-degrading ectoenzyme: e

20060293248 - Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the... Agent: Sonnenschein Nath & Rosenthal LLP For Paula Evans

20060293250 - Crystalline sugar compositions and method of making: Described are novel crystalline pivaloyl furanoses and methods of crystallizing the pivaloyl furanoses. These compounds are useful as intermediates in the synthesis of compounds such as the deoxyjirimycins and nojirimycins and are particularly useful as intermediates for production on a multi-kg scale. Particular crystalline compounds include 1,2,3,6-tetrapivaloyl-α-D-galactofuranose, 1,2,3,6-tetrapivaloyl-α-L-altrofuranose, and 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-α-D-galactofuranose.... Agent: Baker & Botts

20060293253 - Indole compounds useful for the treatment of cancer: The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20060293252 - Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof: e

20060293249 - Porphyrin derivatives:

20060293251 - Substituted indazole-o-glucosides: Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20060293254 - Podophyllotoxin: The invention relates to podophyllotoxins, uses thereof and methods of their production.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20060293255 - Method for regulating nutrient absorption with ginsenosides: There is provided a method for regulating the absorption of a nutrient in a subject, including administering to the subject an effective amount of a ginsenoside compound purified from Panax notoginseng for modulating transportation of the nutrient across gut cells of the subject.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20060293259 - Compositions and methods of use of derivatized flavanols: The invention relates to compositions containing derivatized flavanols such as methylated flavanols, and methods of use thereof for prophylactic or therapeutic treatment of a human or a veterinary animal for example as anti-platelet agents.... Agent: Nada Jain, P.C.

20060293258 - Method and composition to treat skin ulcers: The invention is directed to a method for treating ulcers, including ulcers of the lower leg, by topical plus oral administration of proanthocyanidins to a patient.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. The Chrysler Center

20060293257 - Methods for the treatment of scar tissue: A topical composition and method for the reduction of scar tissue and/or improving the appearance of scar tissue after it has formed. The topical composition includes one or more flavonoids formulated in a pharmaceutically acceptable topical carrier. The method includes the step of topically applying a composition including one or... Agent: Knoble, Yoshida & Dunleavy

20060293256 - Remedy or preventive for kidney disease and method of diagnosing kidney disease: A novel agent for therapy and/or prevention of kidney diseases as well as a diagnostic method (detection method) of kidney diseases is disclosed. The agent for therapy and/or prevention of kidney diseases comprises as an effective ingredient a substance which inhibits casein kinase 2. The diagnostic method of kidney diseases... Agent: Birch Stewart Kolasch & Birch

20060293260 - Useful high load concentrate compositions for control of ecto-and endo-parasites: High load concentrate compositions comprising metaflumizone, a substantially water-insoluble anti-parasitic macrolide compound,such as moxidectin, an optional bridging agent, a surfactant, and a suitable carrier solvent are prepared. These compositions may be topically administered to animals, and are useful for preventing or treating ectoparasitic infestations in warm-blooded animals for prolonged periods... Agent: Wyeth Patent Law Group

20060293261 - Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli: For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20060293268 - Antisense antiviral compounds and methods for treating foot and mouth disease: An antiviral antisense composition and method for treating foot-and-mouth disease virus (FMDV) in veterinary animals is disclosed. The composition contains an antisense compound that has a sequence effective to target at least 12 contiguous bases of an FMDV RNA sequence within a region of the positive-strand genomic RNA defined by... Agent: Perkins Coie LLP

20060293269 - Antisense modulation of superoxide dismutase 1, soluble expression: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of... Agent: Knobbe, Martens, Olson & Bear, LLP

20060293267 - Dual functional oligonucleotides for use as anti-viral agents: The present invention is based, in part, on the discovery that endogenous mRNAs, such as viral miRNAs, can be recruited for translational repression of target mRNAs, such as viral target mRNAs. The RNA-silencing agents and the methods described herein, thereby provide a means of treating viral infections, of treating diseases... Agent: Lahive & Cockfield, LLP

20060293262 - Inhibition of gene expression using rna interfering agents: The present invention is based, at least in part, on the discovery of compositions and methods for the treatment and prevention of infectious diseases or disorders, e.g., HIV infection, AIDS, and AIDS-related diseases. In particular, the present invention pertains to methods of modulating cellular gene expression or protein activity, e.g.,... Agent: David S Resnick Nixon Peabody

20060293270 - Methods and compositions for treating ocular disorders: This invention relates to methods of treating ocular disease. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat such disease.... Agent: (osi) Eyetech, Inc.

20060293265 - Methods involving aldose reductase inhibitors: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of sepsis and autoimmune diseases, including Type I diabetes and rheumatoid arthritis. The invention also pertains to preventing the loss of cardiac muscle contractibility.... Agent: Fulbright & Jaworski L.L.P.

20060293266 - Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure: The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and... Agent: Thelen Reid & Priest LLP Leslie G. Restaino

20060293263 - Preparation for preventing contact of pathogenic matter with living organism: Intermolecular mutual recognition between pathogenic matter, such as allergen group or disease-causing microbe, capable of functioning at the attachment thereof to living organism and a living organism is inhibited by the use of pectins or nucleic acids.... Agent: Young & Thompson

20060293271 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060293272 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060293264 - Stat3 decoy oligonucleotides and uses therefor: A composition is provided that is useful in treating cancers in which STAT3 is activated, such as squamous cell carcinomas including squamous cell carcinoma of the head and neck. The composition comprises an effective amount of a STAT3 decoy and a pharmaceutically acceptable carrier. Also provided are methods of treating... Agent: Jesse A. Hirshman, Esq.

20060293273 - Methods, compositions, and formulations for preventing or reducing adverse effects in a patient: The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a... Agent: Wilson Sonsini Goodrich & Rosati

20060293274 - N²-quinoline or isoquinoline substituted purine derivatives: wherein W represents a hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, or an optionally substituted C1-6 haloalkyl, Y represents a hydrogen, or a saccharide, Q represents a quinoline or isoquinoline. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same,... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20060293275 - Hgf production accelerator containing heparin-like oligosaccharide: The present invention aims to provide an agent for promoting HGF production comprising, as an effective ingredient, a disaccharide comprised of an uronic acid residue (wherein an uronic acid means an iduronic acid or a glucuronic acid, and has the same meaning hereinafter) and a glucosamine residue that are connected... Agent: Wenderoth, Lind & Ponack, L.L.P.

20060293277 - Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making for making them: The present invention provides for compositions of hyaluronic acid cross-linked with at least one other hydrophobic polymer to form a copolymer gel. The preferred composition is a formulation containing hyaluronic acid or its derivatives and a silicone base polymer with a functional group capable of reacting with the preferred cross-linker.... Agent: Sheldon Palmer C/o Galvin & Palmer

20060293278 - Novel therapeutic uses of glucan: A process for the production of β-(1,3)(1,6) glucan from a glucan containing cellular source is described, together with compositions and uses/methods of treatment involving glucan. The process of the invention comprises the steps of: (a) extracting glucan containing cells with alkali and heat, in order to remove alkali soluble components;... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20060293276 - Use of lipid conjugates in the treatment of disease: This invention provides a method of preventing asthma, allergic rhinitis, or chronic obstructive pulmonary disease in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20060293279 - Administration of enoxaparin sodium to patients with severe renal impairment: Methods having novel enoxaparin sodium dosing regimens for patients with severe renal impairment are disclosed. The methods may be used for one or more of preventing thrombotic episodes, treating thrombotic episodes, preventing postoperative venous thrombosis, controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks, treating unstable angina, and treating non-Q-wave... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20060293280 - 1,3-oxathiolane-2-thione compounds: wherein R1 and R2 are the same or different, each of which denotes a straight-chain or branched alkoxy residue with 1 to 6 carbon atoms or an aryloxy or aralkyloxy residue, R3 is different or the same as R1 or R2 or an aliphatic residue, an amino residue, a halogen... Agent: Henkel Corporation

20060293281 - N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions: e

20060293282 - Substituted aminoalkanephosphonic acids: The present invention relates the use of substituted aminoalkanephosphonic acids in treating neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders.... Agent: Novartis Corporate Intellectual Property

20060293284 - Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same: The present invention relates to an acyclic nucleoside phosphonate derivative which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.... Agent: Birch Stewart Kolasch & Birch

20060293283 - Prodrugs of a2b adenosine receptor antagonists: Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states.... Agent: Brian Lewis Cv Therapeutics, Inc.

20060293285 - Aryl phosphate derivatives of d4t: Specific aryl phosphate nucleoside derivatives show activity against HIV without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. Examples of aryl phosphate nucleoside derivatives include aryl phosphate derivatives of d4T having one or more substituents on the aryl group, and wherein the... Agent: Merchant & Gould PC

20060293286 - Resistant-repellent retroviral protease inhibitors: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.... Agent: Proskauer Rose LLP

20060293287 - Storage stable formulation and a process for its preparation: The present invention is directed to a storage stable insecticidal composition comprising one or more Chloronicotynyle compound, in an amount ranging from 0.1 to 5% by weight of the composition, one or more compounds falling within the group of Organophosphorus compounds in an amount ranging from 30 to 75% by... Agent: Jones, Tullar & Cooper, P.C.

20060293288 - Use of resolvins to treat gastrointestinal diseases: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of... Agent: Dorsey & Whitney LLP Intellectual Property Department

20060293289 - Compounds capable of activating cholinergic receptors: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20060293290 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Maryellen Feehery

20060293291 - 2-propylidene-19-nor-vitamin d compounds: 2-propylidene-19-nor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by high bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone... Agent: Andrus, Sceales, Starke & Sawall, LLP

20060293292 - Methods of using acyl hydrazones as seh inhibitors: Disclosed are hydrazine compounds useful as soluble epoxide hydrolase (sEH) inhibitors for treating cardiovascular diseases.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20060293294 - Method for treatment or prevention of androgen deficiency: This invention relates to a method for the treatment or prevention of androgen deficiency in a male individual by administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof. Furthermore, the invention concerns methods for... Agent: Fitzpatrick Cella Harper & Scinto

20060293295 - Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6s)-tetrahydrofolate: The present invention relates to a pharmaceutical composition which may comprise progestogens, preferably drospirenone, estrogens, preferably ethinylestradiol and 5-methyl-(6S)-tetrahydrofolate, which may be employed as oral contraceptive and moreover prevents disorders caused by folate deficiency in the consumers, in particular cardiovascular disorders and, after conception of the embryo, congenital malformations caused... Agent: Frommer Lawrence & Haug

20060293293 - Salmeterol and ciclesonide combination: The invention relates to pharmaceutical compositions containing combinations of salmeterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.... Agent: Nath & Associates PLLC

20060293296 - Process for the preparation of cefpodoxime procetil: A process for the preparation of cefpodoxime proxetil of high purity conforming to pharmacopoeial specifications.... Agent: Cooper & Dunham, LLP

20060293298 - Compounds: p

20060293301 - Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity,... Agent: Woodcock Washburn LLP

20060293300 - New substituted thiophene carboxamides, process for their preparation and their use as medicaments: e

20060293299 - Substituted 3-alkyl and 3-alkenyl azetidine derivatives: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20060293297 - Cyanofluoropyrrolidine derviative: R3 represents a group represented by the formula: —N(R4)COR5, —N(R4)SO2R5, —NR4R6, —SO2R5, —SO2NR4R5, —OCONR4R5, —CH═CH—R7 or —C≡C—R7, or represents a heteroaryl group selected from a heteroaryl group which contains at least one oxygen and/or sulfur atom and which may further contain a nitrogen atom, and a 6-membered nitrogen-containing aromatic ring... Agent: Sughrue Mion, PLLC

20060293303 - Antiprotozoal imidazopyridine compounds: Compounds described by the Formula (I) or (II): or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination... Agent: Merck And Co., Inc

20060293302 - Imidazopyridine-derivatives as inducible no-synthase inhibitors: m

20060293304 - Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein: A process is provided for preparing triazole substituted azaindoleoxoacetic piperazine derivative. Novel intermediates produced in the above process, and novel N-1 and amorphous forms of a 1,2,3-triazole substituted azaindoloxoacetic piperazine derivatives and processes for producing such novel forms are also provided.... Agent: Louis J. Wille Bristol-myers Squibb Company

20060293305 - Preparation of hymenialdisine derivatives and use thereof: The synthesis and biological activity of indoloazepines and acid amine salts thereof which are structurally related to naturally-occurring hymenialdisine is disclosed. Naturally-occurring hymenialdisine obtained from the sponge is a potent inhibitor of production of cytokines interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α). The chemically-synthesized indoloazepines of the invention also inhibit... Agent: Mcleod & Moyne, P.C.

20060293306 - Viral polymerase inhibitors: e

20060293310 - Derivatives of 1-piperazine-and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme: Wherein m, R1 and R2 are as defined herein. The invention also relates to the use of the compound in therapeutics. More specifically, the compounds of the invention are inhibitors of the FAAH enzyme, and therefore, can be used for the treatment of various disorders associated with FAAH enzyme, which... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20060293309 - Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors: The instant invention features compounds, for example, 5-HT3 receptor antagonists, having a peripherally restricted mode of action such that the compounds affect 5-HT3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compounds are particularly useful in treating disorders or conditions ameliorated... Agent: Lahive & Cockfield, LLP

20060293307 - Oxazolidinone derivatives as antimicrobials: The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including... Agent: Ranbaxy Inc.

20060293308 - Pyridyl derivatives and their use as therapeutic agents: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein W, V, x, y, R1, R2, R3, R4, R5, R6, R7, R7a, R8, R8a, R9, R9a, R10... Agent: Osha Liang L.L.P.

20060293311 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.... Agent: Foley & Lardner LLP

20060293312 - Method of improved diuresis in individuals with impaired renal function: Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or... Agent: Knobbe Martens Olson & Bear LLP

20060293313 - New phenylpiperazines: s

20060293314 - 4- piridinylmethylsulphonamide derivatives as fungicidal plant protein agents: X is phenyl, naphthyl or a five- or six-membered saturated, or partially unsaturated or aromatic heterocycle which is attached via a carbon atom and contains one to four heteroatoms from the group consisting of O, N and S, where X may be substituted according to the description; Processes for preparing... Agent: Birch Stewart Kolasch & Birch

20060293315 - Intermediates of novel heterocyclic compounds having antibacterial activity and process for their preparation: i

20060293316 - Hexahydro-pyrrolo-isoquinoline compounds: Certain hexahydro-pyrrolo-isoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20060293317 - Use of non-steroidal progesterone receptor modulators: r

20060293318 - Stereospecifically substituted benzo[1,3]dioxolyl derivatives:

20060293320 - Heteroaryl derivatives for treating viruses: Disclosed are compounds, compositions, and methods for treating Flaviviridae family virus infections.... Agent: Foley & Lardner LLP

20060293319 - Oxindole derivatives: s

20060293321 - 2-heterosubstituted 3-aryl-4h-1-benzopyran-4-ones as novel therapeutics in breast cancer: The present invention provides 2-heterosubstituted 3-aryl-4H-benzopyran-4-one compounds for the treatment of cancers, namely breast cancer. This invention further provides a method of synthesis of 2-(alkylthio)isoflavones that can be carried out at ambient conditions. This invention further provides a method of synthesis of the 2-heterosubstituted 3-aryl-4H-benzopyran-4-one from a 2-(alkylthio)isoflavone. The invention... Agent: Calfee Halter & Griswold, LLP

20060293322 - Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders: The present invention relates to a compound of Formula (I) and its use in treating hyper-proliferative disorders.... Agent: Jeffrey M. Greenman

20060293323 - Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies: Administration of an irreversible tyrosine kinase inhibitor such as CI-1033 in combination with one or more other antineoplastic agent(s), or ionizing radiation is synergistic for treating cancer.... Agent: Pfizer Inc

20060293324 - Pyrimidine compounds: This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the... Agent: Fish & Richardson PC

20060293325 - Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments: where Z is an amine, alcohol, or thiol-containing group, and Y is an alkyl-containing amine. Methods of producing such compounds and using them to treat patients with diabetes and obesity are also disclosed. The present invention also relates to treating such conditions with GADPH inhibitors and screening compounds useful for... Agent: Nixon Peabody LLP - Patent Group

20060293326 - 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases: The invention relates to 2-Heteroaryl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases. The present invention relates to compounds of the general formula (I) in which R1 denotes 5- to 10-membered heteroaryl, which is optionally substituted by... Agent: Jeffrey M. Greenman

20060293327 - Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof: A composition containing an extremely poorly water-soluble drug and obtained by treating, with a supercritical fluid or subcritical fluid of carbon dioxide, a mixture comprising a porous silica material and the extremely poorly water-soluble drug; and its production process. The porous silica material has an average pore diameter in a... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20060293328 - Linear dicationic terphenyls and their aza analogues as antiparasitic agents: Novel dicationic terphenyl compounds and their aza analogues. Methods for combating microbial infections with novel dicationic terphenyl compounds and their aza analogues. Processes for synthesizing novel dicationic terphenyl compounds and their aza analogues.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20060293329 - Substituted enaminones, their derivatives and uses thereof: The present invention is related substituted enaminones represented by a compound of Formula I that are novel allosteric modulators of α7 nAChRs. The invention also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on α7 nAChRs in a mammal by administering an effective amount of... Agent: Heller Ehrman LLP

20060293330 - Hiv replication inhibiting purine derivatives: e

20060293334 - Nitrogen-containing heteroaryl compounds having inhibitory activity against hiv integrase:

20060293331 - Process of synthesizing tadalafil: The present invention provides tadalafil of high purity and processes of making such tadalafil by cyclization of TDCl in a solution.... Agent: Kenyon & Kenyon LLP

20060293332 - Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists: Disclosed are sulfonylquinoxalone acetamide derivatives useful as bradykinin antagonists.... Agent: Foley & Lardner LLP

20060293333 - Therapeutic amides: wherein A, X, Y, and Z are as defined in the specification. The compounds are effective anti-tumor agents. The invention also provides pharmaceutical compositions comprising a compound of the above formula or a salt thereof, intermediates useful for preparing a compound of the above formula, and therapeutic methods comprising administering... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20060293335 - Riboflavin derivative and its manufacture and uses: The invention discloses riboflavin derivatives, and a process of preparing the same, and their applications. The w/o suspending preparation of the riboflavin derivatives has high stability, and the effects could last for 3 months after intramuscular injection at dose of 150 mg. This invention increases significantly the bioavailability of riboflavin... Agent: Ladas & Parry LLP

20060293336 - C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions: e

20060293337 - P2x7 receptor antagonists and their use: The invention provides compounds of formula (IA), processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.... Agent: Fish & Richardson P.C.

20060293338 - Novel chemical compounds: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060293340 - 2-aminopyrimidine derivatives as raf kinase inhibitors: This application discloses compounds that inhibit Raf kinase having the formula (I), wherein R1 is a phenyl radical or a heteroaryl radical; and R2 is a phenyl radical; or an N-oxide or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of proliferative diseases, such as cancer.... Agent: Novartis Corporate Intellectual Property

20060293341 - Alkyl sulfonamide derivatives: This invention is directed to alkyl sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20060293339 - Biaryl substituted 6-membered heterocycles as sodium channel blockers: Biaryl substituted pyridine, pyrimidine and pyrazine compounds are sodium channel blockers useful for the treatment of pain. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with,... Agent: Merck And Co., Inc

20060293343 - Pyrimidine derivatives: a

20060293344 - Therapeutic compounds:

20060293342 - Tie-2 modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20060293345 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 inhibitors.... Agent: Hoffmann & Baron, LLP

20060293346 - Fungicidal mixtures: e

20060293347 - Pharmaceutically active compounds: wherein R1, R2, R4 and R13 are as defined or a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or pro-drug thereof: are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of,... Agent: Pfizer Inc.

20060293348 - Novel compounds: Novel substituted 2, 4, 8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060293349 - 5-chloro-4-alkyl-3,4-dihydro-quinazolin-2-ylamine derivatives: v

20060293351 - Promotion of wound healing: A promotor of wound healing and an inhibitor of formation of a urethral stricture, particularly following surgical intervention or infection in the area. Specifically, the most preferred compound of the present invention, Halofuginone, can be used to prevent collagen deposition from occurring within the lumen of the urethra after such... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20060293350 - 8-alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines: n are as described in the specification and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I can be used for the treatment of 5-HT5A receptor antagonists related diseases, which include depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory... Agent: Hoffmann-la Roche Inc. Patent Law Department

20060293353 - Matrix metalloproteinase inhibitors: R14 and R15 each independently represent H, C1-6 alkyl, C1-4 alkylaryl or C1-4 alkylheteroaryl or together with the functionality to which they are attached R14 and R15 form a heterocyclic or fused heterocyclic group; and physiologically functional derivatives thereof, corresponding processes for preparation, pharmaceutical formulations containing them and their use... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060293352 - Phenoxiacetic acid derivatives: The invention relates to certain 2-substituted phenoxyacetic acid derivatives of formula (I), in which the variables are as defined in the claims, useful in the treatment of diseases or conditions in which modulation of the CRTh2 receptor is beneficial, such as asthma and rhinitis.... Agent: Fish & Richardson P.C.

20060293355 - Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s)-3, 5-dihydroxyhept-6-enoicacid] calcium salt: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.... Agent: Morgan Lewis & Bockius LLP

20060293354 - Pyrimidine derivatives and their use as cb2 modulators: The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20060293356 - Methods for treating smooth muscle contractions using trospium: Methods are disclosed using trospium, an antimuscarinic smooth muscle relaxant, for the treatment of smooth muscle disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.... Agent: Nields & Lemack

20060293357 - Intermediates for synthesis of vinblastine, process for preparation of the intermediates and process for synthesis of vinblastines: A method for synthesis of the compound of general formula A utilizing radical ring forming reaction of thioanilides and using the compound of general formula B as the starting material, synthesizing thioanilide of general formula C by the reaction with compound 1 and the formation of a 11-membered ring by... Agent: Hahn & Voight PLLC

20060293358 - Tyrosine kinase inhibitors: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20060293359 - Methods and compositions for the treatment of diabetes: Disclosed is a method for treating symptoms of diabetes using an agonist of the α2B and/or α2C adrenergic receptor subtypes that lacks (a) significant α2A adrenergic receptor activity or (b) significant α1A adrenergic receptor activity, or that lacks both (a) and (b).... Agent: Allergan, Inc.

20060293360 - 4-(2-phenyloxyphenyl)-piperidine or-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors: The invention provides compounds represented by the general formula (I) wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.... Agent: Darby & Darby P.C.

20060293361 - Compounds: e

20060293362 - Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them: The invention relates to nitro-substituted 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention... Agent: Fulbright & Jaworski, LLP

20060293363 - Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles: Improved processes for preparing substituted 2-(2-pyridylmethyl)sulfinyl-1H-benzimidazoles are disclosed.... Agent: Kenyon & Kenyon LLP

20060293364 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: p

20060293366 - Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors: inhibit the formation of the β-amyloid peptide (β-A4) and are, therefore, useful in the treatment of pathologies in which a β-amyloid peptide (β-A4) formation inhibitor provides a therapeutic benefit. Particular such pathologies are senile dementia, Alzheimer's disease, Down's syndrome, Parkinson's disease, amyloid angiopathy, cerebrovascular disorders, frontotemporal dementias and Pick's disease,... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20060293365 - Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics: h

20060293367 - Amorphous n-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide: An amorphous drug, processes for making it, compositions containing it and methods of treatment of diseases using it are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20060293368 - Amorphous n-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride: Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride, processes for making it, compositions containing it and methods of treatment of diseases using it are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20060293369 - Fungicidal composition comprising a pyridylmethylbenzamide derivative and chlorothalonil: A fungicidal composition comprising at least a pyridylmethylbenzamide derivative of general formula (I) and a chloronitrile derivative which is chlorothalonil; in a compound (I)/chlorothalonil weight ratio of from 0.005 to 1. Method for preventively or curatively combating the phytopathogenic fungi of crops by using this composition.... Agent: Ostrolenk Faber Gerb & Soffen

20060293370 - Sulfonamide compounds and uses thereof: Compounds that modulate GHS-R are described, for examples compounds formula (I)... Agent: Fish & Richardson PC

20060293371 - Prodrug and process for producing the same: m

20060293372 - Beta-sheet mimetics and methods relating to the use thereof: β-sheet mimetics and methods relating to the same are disclosed. The β-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a β-sheet mimetic, or use of the same for the manufacture of... Agent: Seed Intellectual Property Law Group PLLC

20060293373 - Gamma-secretase inhibitors: x

20060293374 - Substituted isothiazolones: and pharmaceutically acceptable forms thereof useful as inhibitors of cPLA2 and a method for preventing, treating or ameliorating a cPLA2 mediated inflammatory related disease, disorder or condition using a compound of Formula (I) and, more particularly, for preventing, treating or ameliorating a cPLA2 mediated inflammatory related disease, disorder or condition... Agent: Philip S. Johnson Johnson & Johnson

20060293377 - Amorphous and polymorphic forms of telmisartan sodium: Provided is the amorphous form of telmisartan sodium and the preparation thereof. Also provided are the telmisartan sodium polymorph crystal Forms 0 to XIII and XV to XX and preparations thereof. Also provided are pharmaceutical composition of amorphous and polymorphic forms of telmisartan sodium or mixtures thereof, and methods of... Agent: Kenyon & Kenyon LLP

20060293376 - Benzopyran derivatives substituted with a benzimidazole derviative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them: The present invention relates to benzopyran derivatives substituted with a benzimidazole derivative, or pharmaceutically acceptable salts thereof, a preparation method of the same and pharmarceutical compositions containing them. Benzopyran derivatives substituted with a benzimidazole derivative, represented in Formula (1), have the function of protecting heart from ischemia-reperfusion without side effect... Agent: Lucas & Mercanti, LLP

20060293375 - Crystal of benzimidazole derivative and process for producing the same: Various crystal forms of 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazol-2-ylthio)butanoic acid from a solvent, and a process for production thereof are provided.... Agent: Sughrue Mion, PLLC

20060293378 - Method of lowering intraocular pressure: A method of lowering intraocular pressure and/or treating glaucoma comprises administering to a patient a therapeutically effective amount of a fused pyrrolocarbazole derivative, or a pharmaceutically acceptable salt or prodrug thereof.... Agent: Bausch & Lomb Incorporated

20060293379 - Quaternary salt ccr2 antagonists: m

20060293380 - Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck And Co., Inc

20060293381 - Fungicidal effect by regulating signal transduction pathways: The present invention concerns methods of treating fungal infections and methods of screening compounds for activity in treating fungal infections. Methods of the invention include using an active compound such as fludioxonil to treat a Cryptococcus neoformans infection. Also included are methods and pharmaceutical compositions useful for treating fungal infections... Agent: Myers Bigel Sibley & Sajovec

20060293382 - Stable warfarin sodium liquid formulation and method of making same: A stable liquid composition comprising warfarin sodium, glycerin, an alcohol such as ethanol, and a pH buffer such as a phosphate buffer providing a pH above 7 is provided. The stability of the composition is characterized by the amount of warfarin sodium in the composition degraded after 1 month at... Agent: Winston & Strawn LLP Patent Department

20060293383 - Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain: wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R1 and R2 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl... Agent: Philip S. Johnson Johnson & Johnson

20060293384 - Isethionyl nitrates and compounds thereof: in which the cation M is selected from the group consisting of: hydrogen, alkali metal cations, alkaline earth metal cations, Group III metal cations, transition metal cations, ammonium ions (including organic-substituted ammonium cations), including mixtures of any two or more of the foregoing; R1 and R2 are each independently selected... Agent: Christopher J. Whewell Western Patent Group

20060293385 - Vitamin d receptor modulators: The present invention relates to novel, non-secosteroidal, sulfonate and sulfonamide functional diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.... Agent: Eli Lilly & Company

20060293386 - Method for treating cancer: It is an object of the present invention to provide a method for cancer treatment to suppress cancer, specifically hepato cellular carcinoma. There is discovered effective suppression of the progression of hepatocellular carcinoma with gabexate mesilate, a non-anticancer drug that has not been used as an anticancer drug. Gabexate mesilate... Agent: Jordan And Hamburg LLP

20060293387 - Agent for lowering neutral fat concentration in blood: An agent for lowering neutral fat concentration in blood and a therapeutic agent for a disease to which neutral fat in blood is related, the agent containing astaxanthin and/or esters thereof. The agent for lowering neutral fat concentration in blood according to the present invention is useful for treating various... Agent: Le-nhung Mcleland

20060293388 - Pomolic acid, its isomers, derivatives and their uses, pharmaceutical composition, method to prepare the pharmaceutical composition and method for treating multidrug resistant tumours: The present invention describes the use of pomolic acid, its derivatives and pharmaceutical preparations derived from them as anti-neoplasic agents in the treatment of multidrug resistant tumors. In relation to other drugs that present anti-MDR activity, these substances do not require the concomitant use of reversers to exert their anti-MDR... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20060293389 - Process for producing injectable gabapentin compositions: Injectable compositions containing gabapentin and processes for preparing sterile injectable compositions containing gabapentin are discussed. The process includes subjecting the compositions to heat. Heating results in increased production of gabapentin lactam, which has previously been shown to be toxic. Surprisingly, heated injectable compositions containing gabapentin are found to be non-toxic... Agent: Medtronic, Inc.

20060293390 - Diflunisal for the treatment of cancer: The invention is directed to the use of Diflunisal for the preparation of a medicament for the treatment of cancer, wherein the medicament is adapted for administration so that a molecular ratio of 4:1 to 6:1 of interstitial Diflunisal to interstitial albumin is provided.... Agent: Reed Smith LLP

20060293391 - Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases: The invention describes the use of deoxyspergualin (DSG) or an analogue thereof for the preparation of a medicament for the treatment of and/or prophylaxis against hyperreactive inflammatory diseases and autoimmune diseases, wherein the treatment is performed in cycles.... Agent: Frommer Lawrence & Haug

20060293392 - Benzamide derivatives and uses related thereto: e

20060293393 - Iptakalim hydrochloride for decreasing nicotine use: A method for decreasing nicotine and other substance use in humans is disclosed. Iptakalim hydrochloride (IPT) is a novel nicotine acetylcholine receptor (nAChR) blocker. According to the disclosed method, IPT is used to block human α4β2-nAChR function. Specifically, IPT exhibits a selective blockade of α4 subunit-containing human nAChR subtypes. According... Agent: Jennings, Strouss & Salmon, P.L.C

20060293394 - Combretastatin analogs with tubulin binding activity: Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20060293395 - Methods for treating a mammal before, during and after cardiac arrest: Methods for treating mammals before, during and after cardiac arrest are disclosed. Pharmaceutical compositions comprising levosimendan useful for such treatment also are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20060287220 - Water soluble paclitaxel prodrugs: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include... Agent: Foley And Lardner LLP Suite 500

20060287221 - Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia: Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide.... Agent: Novo Nordisk, Inc. Patent Department

20060287222 - Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060287224 - Glycopegylated erythropoietin formulations: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified... Agent: Morgan, Lewis & Bockius LLP (sf)

20060287223 - Remodeling and glycoconjugation of peptides: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide.... Agent: Morgan, Lewis & Bockius LLP (sf)

20060287225 - Integrin inhibitors for the treatment of eye diseases: Methods and compositions for prophylaxis and/or treatment of diseases of the eye using antagonists of the integin receptors αvβ3 and/or αvβ5. The compositions can be nanoparticles and are administered to the eye by injection into the vitreous body of the eye.... Agent: Millen, White, Zelano & Branigan, P.C.

20060287232 - Antimicrobial peptides: Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and... Agent: Peters Verny Jones & Schmitt, L.L.P.

20060287226 - Characterization of a membrane estrogen receptor: The present invention discloses the identification of a novel membrane associated estrogen receptor, termed mER. The membrane associated receptor is involved in rapid signal transduction. Amino acid sequences, nucleic acid sequences, vectors, and host cells are also discussed. Additionally, methods of detecting agonists and antagonists for the receptor are disclosed... Agent: Darby & Darby P.C.

20060287230 - Compositions which can be used for regulating the activity of parkin: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating,... Agent: Wiley, Rein & Fielding, LLP Attn: Patent Administration

20060287235 - Crystallization of igf-1: Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method... Agent: Heller Ehrman LLP

20060287228 - Expression of active human factor ix in mammary tissue of transgenic animals: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic animals of the present invention are produced by introducing into developing embryos DNA that encodes Factor IX, such that... Agent: Jayme Huleatt Cooley Godward LLP

20060287227 - Gonadal function improving agents: Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing/treating sterility,... Agent: Edwards & Angell, LLP

20060287233 - Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells: The present invention provides materials and methods for the treatment of diabetes. Using the materials and methods of the invention, the loss of pancreatic β-cells can be slowed and/or prevented. In addition, the materials and methods of the invention can be used to regenerate pancreatic β-cells.... Agent: Connolly Bove Lodge & Hutz LLP Suite 800

20060287236 - Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases: Methods and compositions are provided for the diagnosis and treatment of iron overload diseases and iron deficiency diseases.... Agent: Jones Day

20060287229 - Novel cd40 variants: The invention concerns CD40 skipping 5 nucleic acid sequences and amino acid sequences obtained by alternative splicing of CD40, pharmaceutical compositions comprising said sequences and methods for treatment of a disease, wherein a beneficial therapeutic effect is achieved by the up regulation of the CD40-R-CD40-L interaction. An antibody capable of... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20060287237 - Rhob as a suppressor of cancer cell growth, cell transformation, and metastasis: The present invention concerns the use of the protein RhoB and its variants to inhibit cancer cell growth, migration, invasion, metastasis, malignant cell transformation, and/or to modulate oncogenic signaling, wherein introducing RhoB directly, or indirectly via a nucleic acid sequence encoding RhoB, into a malignantly transformed cell or a cancerous... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20060287231 - Therapeutic uses of kallikreins: The present invention relates to therapeutic applications of kallikreins and compositions containing them for treating, preventing and/or ameliorating cancers, especially epithelial cancers, such as ovarian, breast and cervical cancer.... Agent: Foley And Lardner LLP Suite 500

20060287234 - Wound healing: Methods for accelerating and/or improving wound healing in a subject by administering vascular endothelial growth factor (VEGF) are provided.... Agent: Genentech, Inc.

20060287238 - Novel combinations of dnak inhibitors with known antibacterial agents: Compositions, methods and kits are provided comprising (a) a therapeutically effective amount of a DnaK inhibitor; and (b) a therapeutically effective amount of a known antibacterial agent. Such compositions, methods and kits are useful in the treatment of various bacterial infections.... Agent: Norton & Diehl LLC

20060287239 - Biologically active peptides: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced thereform are also disclosed.... Agent: EagleIPLimited

20060287240 - Method of stimulating prosaposin receptor activity: A method for stimulating prosaposin receptor activity in a cell by transfecting the cell with a DNA or RNA molecule encoding prosaposin or a prosaposin receptor agonist. The DNA or RNA molecule is administered either in vivo or used to transfect neural cells or neural stem cells ex vivo followed... Agent: Kenyon & Kenyon LLP

20060287245 - Anti-tumor agents: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in... Agent: Wolf Greenfield & Sacks, PC

20060287241 - Combination comprising n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an LHRH analogue and/or a bisphosphonate is described.... Agent: Astrazeneca R&d Boston

20060287242 -